Recursion Pharmaceuticals
A U.S. biotechnology company that conducts drug discovery through automated laboratories, robotic operations, and high-throughput screening platforms, integrating artificial intelligence with large-scale biological experimentation.
Timeline (last 90 days)
In November 2024, Recursion acquired Exscientia for $688 million in stock, and the combined company says it has more than 10 clinical and preclinical programs.
Recursion's REC-4881 (a MEK1/2 inhibitor) for familial adenomatous polyposis reduced polyp burden by a median of 43% at week 13 and 53% at week 25.
Recursion's REC-7735 targets mutant forms of PI3K-alpha and took only 10 months from first chemical hit to IND clearance, with selectivity for the mutant protein more than 100 times that for the healthy version.
Companies such as Recursion Pharmaceuticals and Insitro build their core competitive barriers through robotic operations, microfluidic technology, and large-scale parallel experiments.
All Facts (5)
Recursion Pharmaceuticals、Exscientia等AI制药公司已获得数十亿美元融资
75%UnverifiedRecursion's REC-4881 (a MEK1/2 inhibitor) for familial adenomatous polyposis reduced polyp burden by a median of 43% at week 13 and 53% at week 25.
50%UnverifiedRecursion's REC-7735 targets mutant forms of PI3K-alpha and took only 10 months from first chemical hit to IND clearance, with selectivity for the mutant protein more than 100 times that for the healthy version.
50%UnverifiedCompanies such as Recursion Pharmaceuticals and Insitro build their core competitive barriers through robotic operations, microfluidic technology, and large-scale parallel experiments.
50%UnverifiedIn November 2024, Recursion acquired Exscientia for $688 million in stock, and the combined company says it has more than 10 clinical and preclinical programs.
50%